Young Adult EC Use and Respiratory Outcomes

November 7, 2023 updated by: Alayna Tackett, Ohio State University Comprehensive Cancer Center
E-cigarette (EC) use continues to increase among youth, and EC may be detrimental to youth respiratory health. Public health officials and the Food and Drug Administration (FDA) can now regulate ECs. The proposed study uses naturalistic assessments called ecological momentary assessment (EMA) to understand how ECs use may impact the respiratory health of youth and young adult users compared to never-using peers.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Using a prospective longitudinal design, 150 youth and young adults aged 18-25 years (100 exclusive-EC users; 50 never-users) will complete 5 sessions (baseline, 3-,6-, 9-, and 12-months). Sessions will include naturalistic measures such as measures of respiratory health, questionnaires, and nasal epithelial lining fluid (NELF) nasal samples. To assess acute changes in pulmonary functioning related to tobacco product use, participants will complete twice daily EMA and home-based spirometry for the 2 weeks following the Day 1 session and the 2 weeks prior to each follow-up zoom session. Never-users will participate in a brief 15-30-minute individual interview consisting of questions related to reasons for never-EC use and other protective factors that will be used to build future prevention messaging.

Study Type

Observational

Enrollment (Estimated)

300

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Ohio
      • Columbus, Ohio, United States, 43214
        • Recruiting
        • The Ohio State University
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

15 years to 21 years (Adult)

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

The present proposal, a study of e-cigarette use among youth and young adults, will include both females and racial/ethnic minorities.

Description

Inclusion Criteria:

  1. own a smartphone and willing to add study EMA and spirometry application to it.
  2. a current exclusive-EC user (endorse ≥weekly use over the past 3 months) and report never trying OTPs
  3. between the ages of 18-25 years old at the time of enrollment
  4. read and speak English
  5. willing to complete five, 2-week periods of daily EMA and home-based spirometry
  6. never-users must indicate never trying any tobacco product to be eligible for enrollment

Exclusion Criteria:

  1. self-reported diagnosis of lung disease including cystic fibrosis or chronic obstructive pulmonary disease; we will not exclude youth who have asthma, but will incorporate this as a covariate during analyses
  2. unstable or significant psychiatric conditions (past and stable conditions will be allowed)
  3. history of cardiac event or distress within the past 3 months
  4. are currently pregnant, planning to become pregnant, or breastfeeding

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Current E-Cigarette Users
Monitoring current e-cigarette users
Never E-Cigarette / Tobacco Users
Monitoring never users of any tobacco or e-cigarette products.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Spirometry to measure the change from baseline in forced vital capacity (FVC)
Time Frame: Baseline, 3-month, 6-month, 9-month, 12-month
Spirometry (a pulmonary function diagnostic test) will be completed during each session. For e-cigarette users, assessments will be completed in session.
Baseline, 3-month, 6-month, 9-month, 12-month
Spirometry to measure the change from baseline in forced expiratory volume (FEV)
Time Frame: Baseline, 3-month, 6-month, 9-month, 12-month
Spirometry (a pulmonary function diagnostic test) will be completed during each session. For e-cigarette users, assessments will be completed in session.
Baseline, 3-month, 6-month, 9-month, 12-month
Level of dependence by product type will be examined.
Time Frame: Baseline, 3-month, 6-month, 9-month, 12-month
Changes in product use evaluated with an evaluation of the changes in dependence using the Hooked on Nicotine Checklist (HONC).
Baseline, 3-month, 6-month, 9-month, 12-month
Respiratory health measures by nasal swab.
Time Frame: Baseline, 3-month, 6-month, 9-month, 12-month
Nasal epithelial lining fluid (NELF) samples will provide objective data on respiratory health (e.g., markers of inflammation, host defense, and lung injury) and will provide estimates of nicotine exposure/use via cotinine (i.e., the predominate metabolite of nicotine) will also be examined to provide objective indicators of recency of EC and/or OTP use.
Baseline, 3-month, 6-month, 9-month, 12-month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Alayna Tackett, PhD, The Ohio State Comprehensive Cancer Center

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 15, 2021

Primary Completion (Estimated)

May 15, 2024

Study Completion (Estimated)

July 15, 2024

Study Registration Dates

First Submitted

April 21, 2020

First Submitted That Met QC Criteria

May 14, 2020

First Posted (Actual)

May 20, 2020

Study Record Updates

Last Update Posted (Actual)

November 9, 2023

Last Update Submitted That Met QC Criteria

November 7, 2023

Last Verified

November 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • OSU-23006
  • 1K01HL148907-01 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on E Cig Use

Clinical Trials on Other

3
Subscribe